Tech Company Financing Transactions
Grey Wolf Therapeutics Funding Round
ICG Ventures, Andera Partners and British Patient Capital invested in a $50 million Series B funding round for Grey Wolf Therapeutics. The round was announced on 5/23/2024.
Transaction Overview
Company Name
Announced On
5/23/2024
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to broaden the scope of its ongoing Phase 1/2 clinical trial of its lead immuno-oncology candidate, GRWD5769, in a range of solid tumour types and to expand its research and development (R&D) for its versatile antigen modulation approach into treatments for autoimmune disease indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Milton Park Innovation Centre 99 Park Drive, Milton Park
Abingdon, OX14 4RY
UK
Abingdon, OX14 4RY
UK
Phone
Website
Email Address
Overview
Grey Wolf is a UK and Australian-based drug discovery and development company focused on developing novel immuno-oncology agents. The company was founded in 2017 by experienced industry professionals; Tom McCarthy (Executive Chairman; former President and CEO of Spinifex Pharmaceuticals), and Peter Joyce (CEO; former Project Leader at Vertex Pharmaceuticals).?
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Joyce
Co-Founder
Thomas McCarthy
Browse more venture capital transactions:
Prev: 5/23/2024: Adams Clinical venture capital transaction
Next: 5/23/2024: Remark venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs